KlotoDx
KlotoDx A quick and cost-effective near-patient tool to identify sepsis-related bacteria and antibiotic resistances
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0KlotoDx project word cloud
Explore the words cloud of the KlotoDx project. It provides you a very rough idea of what is the project "KlotoDx" about.
Project "KlotoDx" data sheet
The following table provides information about the project.
| Coordinator |
MOIRAI BIODESIGN S.L.
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.moiraibiodesign.com/index.html |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-09-01 to 2018-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MOIRAI BIODESIGN S.L. | ES (BARCELONA) | coordinator | 50˙000.00 |
Map
Project objective
Sepsis is a common disease caused mostly by bacteria that affects about 30 M people each year worldwide. If not diagnosed on time and treated appropriately, it may be lethal in 30% of cases and the cost for the healthcare system if not detected within the first 24 hours can rise dramatically. Current diagnostic techniques used to detect bacteria in patients’ blood, and identify their antimicrobial resistances, are still based on blood culture which takes more than 1 day and has a very limited detection efficiency. Moirai Biodesign is currently engineering a whole new generation of RNA-based diagnostics using both our in-house and cutting-edge artificial intelligence algorithms to detect ribosomal RNA from bacterial agents and expressed bacterial genes associated to common antibiotic resistances and a patient’s blood sample. Our platform is a near-patient, fast, efficient and cost-effective solution for the early detection and characterization of sepsis-related bacteria which will improve patient’s treatment, avoid broad-spectrum antibiotics’ side-effects and dramatically reduce death rates. Our technology has been preliminary validated for the diagnosis of Acute Promyelocytic Leukemia (APL) and KlotoDx’s main goal is to further adapt, validate and commercialize our disruptive diagnosis device for the identification of sepsis-causing bacteria and their antibiotic resistance genes. To achieve it and place our disruptive near-patient solution in the healthcare market, we envision a total investment of around €2.3 M and we plan to reach the 70% (around €1.6M) by applying for a Phase 2 within the H2020 SME-Instrument programme, once we perform the feasibility study during Phase 1. The increasing need for early sepsis diagnosis aand its characterization in terms of antibiotic resistance boosts KlotoDx’s opportunity to enter the primary care segment in a very disruptive manner.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KLOTODX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "KLOTODX" are provided by the European Opendata Portal: CORDIS opendata.
